We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CVS Health Corporation | NYSE:CVS | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.08 | 0.14% | 57.40 | 57.56 | 57.16 | 57.39 | 9,543,933 | 01:00:00 |
WOONSOCKET, R.I., Sept. 24, 2021 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced that, following approval from the Centers for Disease Control and Prevention (CDC) based on guidance from the organization's Advisory Committee on Immunization Practices (ACIP), select CVS Pharmacy and MinuteClinic locations are now offering the Pfizer-BioNTech COVID-19 booster shot to eligible populations beginning today, Friday, September 24.
Following guidelines set by ACIP and CDC:
Individuals who initially received the Moderna or Johnson & Johnson (Janssen) COVID-19 vaccine are not eligible for a booster at this time, per guidance from the public health agencies.
"We have the experience and the infrastructure to play a leading role in administering booster shots to eligible populations," said Troyen A. Brennan, M.D., MPH, Executive Vice President and Chief Medical Officer of CVS Health. "We also continue to make it as convenient as possible for the unvaccinated to receive their first doses."
Individuals interested in receiving the Pfizer-BioNTech COVID-19 booster or their initial vaccine series are strongly encouraged to make an appointment at CVS.com or MinuteClinic.com to ensure they are able to access the correct vaccine at a convenient time and location.
Currently, each participating CVS Pharmacy and MinuteClinic location is offering either the Pfizer-BioNTech, Moderna, or Johnson & Johnson (Janssen) vaccine, not all three.
When scheduling an appointment on cvs.com, patients will be asked to provide the manufacturer and date of their last COVID-19 vaccine and will be able to schedule an appointment for a Pfizer-BioNTech booster dose if they have had two previous doses with the same vaccine at least six months prior. Per guidance from the CDC, patients will be asked to self-attest to their eligibility as defined by the eligibility guidelines, to help reduce barriers to access for these select populations.
CVS Health has administered more than 34 million COVID-19 vaccines and 32 million COVID-19 tests across the country to-date. The company has played a prominent role in administering third doses to the immunocompromised and is prepared to provide booster shots from other manufacturers, as well as expand vaccine eligibility to ages 5-11, as soon as authorized to do so by public health agencies.
About CVS Health
CVS Health is the leading health solutions company, delivering care in ways no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and our nearly 300,000 dedicated colleagues including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. Wherever and whenever people need us, we help them with their health whether that's managing chronic diseases, staying compliant with their medications, or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system and their personal health care by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Learn more at www.cvshealth.com.
Media contact
Matthew Blanchette
Matthew.Blanchette@cvshealth.com
401-524-6185
View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-health-announces-availability-of-pfizer-biontech-booster-shot-to-eligible-populations-301384931.html
SOURCE CVS Health
Copyright 2021 PR Newswire
1 Year CVS Health Chart |
1 Month CVS Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions